Petdx Raises $62 Million In Series B Financing To Scale Adoption Of Its Canine Multi-Cancer Early Detection Blood Test, Oncok9
Petdx Raises $62 Million In Series B Financing To Scale Adoption Of Its Canine Multi-Cancer Early Detection Blood Test, Oncok9
12/09/21, 9:02 AM
Location
san diegoMoney raised
$62 million
Industry
biotechnology
financial services
health care
community and lifestyle
Round Type
series b
PetDx® today announced the completion of its Series B financing with over $62 million in new capital raised, which is one of the biggest Series B rounds for a pet startup; bringing the company's total funding to date to $72 million. The financing was led by Longview Asset Management with participation by Declaration Partners, Torch Capital, Aperture Venture Partners, Valor Equity Partners, Friedman Bioventure, K4 Family Investments, and Labcorp (NYSE:LH). The company's $10M Series A financing in August 2020 was led by Friedman Bioventure with participation from Petco (Nasdaq:WOOF) and an undisclosed leading pet healthcare company.
Company Info
Location
san diego, california, united states
Additional Info
PetDx® – The Liquid Biopsy Company for Pets is a San Diego-based molecular diagnostics company dedicated to unleashing the power of genomics to improve pet health. The company's flagship product, OncoK9®, enables veterinarians to detect cancer in dogs with a simple blood draw. As a first-in-class multi-cancer early detection (MCED) test, OncoK9 employs cutting-edge genomic analysis that leverages next-generation sequencing (NGS) technology and proprietary bioinformatics algorithms, empowering veterinarians to provide superior care to canine patients. To learn more, visit www.petdx.com.